This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McBride, W. H. Articles by Dougherty, G. J. Search for Related Content PubMed PubMed Citation Articles by McBride, W. H. Articles by Dougherty, G. J.

Genetic Modification of a Murine Fibrosarcoma to Produce Interleukin 7 Stimulates Host Cell Infiltration and Tumor Immunity¹

Departments of Radiation Oncology [W. H. M., S. C.], Surgery [J. S. E.], Pulmonary and Critical Care Medicine [S. M. D., D. K.], and the Jonsson Comprehensive Cancer Center [W. H. M., J. S. E., S. M. D.], University of California at Los Angeles School of Medicine, Los Angeles, California 90024; Terry Fox Laboratory [J. D. T., D. H., G. J. D.], British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z1L3, Canada; and Departments of Medical Genetics [J. D. T., D. H.] and Pathology [G. J. D.], University of British Columbia, Vancouver, British Columbia, V6T1W5, Canada

Retroviral-mediated gene transfer was used to introduce and express the gene for murine interleukin 7 (IL-7) in a fibrosarcoma tumor (FSA). The tumorigenicity of these genetically modified FSA cells was greatly decreased in immunologically intact syngeneic mice but was unaltered in T-cell-deprived mice. IL-7-infected tumors that did grow in intact animals from large size inocula did so slowly and had a high incidence of spontaneous regression. Furthermore, mice that had rejected tumors became specifically immune to challenge with uninfected parental tumor cells.

IL-7-infected FSA growing in intact mice were heavily infiltrated with host T-cells that were presumably responsible for slow growth and tumor regression, and tumor cells were in the minority. Fluorescence-activated cell sorter analysis showed that there was a 530% increase in T-cells in IL-7-infected FSA compared with control tumors. CD8+ T-cells were particularly elevated, but CD4+ lymphocytes were also increased in number, as were eosinophils and basophils. The CD4+:CD8+ ratio in IL-7-infected FSA was 1:1.7 in comparison to 1:0.6 in control tumors. Lymphocytes isolated from IL-7-producing tumors had greatly enhanced cytotoxicity towards uninfected, parental FSA cells. Killing of non-cross-reacting fibrosarcoma line was also increased but to a much lesser extent.

Injection of recombinant human IL-7 directly into established FSA tumors slowed their growth and, in a significant number of instances, caused complete regression. Mice that had rejected tumor became specifically immune. The dose that was needed for this effect was, however, somewhat large: 20 µg twice daily for 10 days. This result contrasts with the efficacy of IL-7 gene infection in stimulating responses to the same tumor. These considerations make IL-7 a good candidate for tumor-directed cytokine gene therapy.

¹ This work was supported by grants from the National Cancer Institute, the British Columbia Health Care Research Foundation, and the National Cancer Institute of Canada. G. J. D. is a National Cancer Institute of Canada Career Scientist.

² To whom requests for reprints should be addressed, at Department of Radiation Oncology, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, CA 90024-1714.

Received 12/16/91. Accepted 5/ 5/92.

This article has been cited by other articles:

				M. R. Graf, R. M. Prins, and R. E. Merchant IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity J. Immunol., January 1, 2001; 166(1): 121 - 129. [Abstract] [Full Text] [PDF]

				R. Zhang, F. H. Straus, and L. J. DeGroot Effective Genetic Therapy of Established Medullary Thyroid Carcinomas with Murine Interleukin-2: Dissemination and Cytotoxicity Studies in a Rat Tumor Model Endocrinology, May 1, 1999; 140(5): 2152 - 2158. [Abstract] [Full Text]

				C. N. Coleman Modulating the Radiation Response Oncologist, August 1, 1996; 1(4): 227 - 231. [Abstract] [Full Text] [PDF]

				C. Coleman Modulating the radiation response Stem Cells, January 1, 1996; 14(1): 10 - 15. [Abstract]